Genital Herpes News and Research

RSS

Offshore rush for herpes vaccine roils debate over U.S. safety rules

Defying U.S. safety protections for human trials, an American university and a group of wealthy libertarians, including a prominent Donald Trump supporter, are backing the offshore testing of an experimental herpes vaccine.

28 Aug 2017

New genital herpes vaccine candidate shows promising results in preclinical tests

Approximately 500 million people around the world are infected with the genital herpes virus known as herpes simplex virus 2 (HSV2).

20 Jan 2017

Slayback Pharma launches Generic Zovirax Ointment 5% for herpes virus infections

Slayback Pharma LLC is pleased to announce the launch of Generic Zovirax Ointment (Acyclovir Ointment) 5%, by its out-licensee - Sandoz (Fougera). Slayback had developed the product and out-licensed the sales and marketing rights to Sandoz.

23 Dec 2016

USPSTF recommends against routine serologic screening for genital HSV infection

The U.S. Preventive Services Task Force recommends against routine serologic screening (via a blood test) for genital herpes simplex virus infection in asymptomatic adolescents and adults, including those who are pregnant.

20 Dec 2016

Study compares medications for treatment of persons with recurrent genital herpes

In a study appearing in the December 20 issue of JAMA, Anna Wald, M.D., M.P.H., of the University of Washington & Fred Hutchinson Cancer Research Center, Seattle, and colleagues compared the medications pritelivir and valacyclovir for reducing genital herpes simplex virus shedding and lesions in persons with recurrent genital herpes.

20 Dec 2016

Psychology researcher explores barriers deterring MSM from seeking information on STIs

A researcher at Birmingham City University is undertaking research into the social and cognitive barriers hindering men who have sex with other men (MSM) from finding out more information about sexually transmitted infections (STIs).

15 Dec 2016

Researchers report promising vaccine strategy for immunizing against herpes viruses

Oral and genital herpes are caused by the herpes simplex virus type 1 (HSV-1) and the herpes simplex virus type 2 (HSV-2), which both cause lifelong infection. HSV-2 infection is associated with increased risk for HIV infection.

4 Aug 2016

ZOTEN nanoparticles can help develop natural immunity against genital herpes

An effective vaccine against the virus that causes genital herpes has evaded researchers for decades. But now, researchers from the University of Illinois at Chicago working with scientists from Germany have shown that zinc-oxide nanoparticles shaped like jacks can prevent the virus from entering cells, and help natural immunity to develop.

28 Apr 2016

New study suggests that Neanderthals across Europe may have diseases carried out of Africa

A new study suggests that Neanderthals across Europe may well have been infected with diseases carried out of Africa by waves of anatomically modern humans, or Homo sapiens. As both were species of hominin, it would have been easier for pathogens to jump populations, say researchers. This might have contributed to the demise of Neanderthals.

11 Apr 2016

Use of OTC medication not always a smart decision for yeast infection

Itching, burning, redness—a yeast infection can be a total pain. While they aren't life-threatening, yeast infections are irritating—both physically and mentally. So, when undesirable symptoms appear 'down there,' should you consult your physician or self diagnose and treat with over-the-counter medications?

9 Mar 2016

Study shows several Envigo rat models susceptible to genital HSV-2 infection

A scientific collaboration between Envigo and the Department of Infectious Disease at the University of Gothenburg, Sweden has unveiled study findings into rat models and their susceptibility to intra-vaginal herpes simplex virus-2 (HSV-2) infection.

2 Feb 2016

Over 3.7 billion people under 50 have genital HSV-1 infection, shows WHO report

More than 3.7 billion people under the age of 50 – or 67% of the population – are infected with herpes simplex virus type 1 (HSV-1), according to the World Health Organization’s first global estimates of HSV-1 infection published today in the journal PLOS ONE.

29 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.

7 Oct 2015

Vaginal silicone ring may protect women against HIV, herpes virus

Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.

From Quest Diagnostics 4 Sep 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings from a pair of new studies could speed up the development of a universally accurate diagnostic test for human herpes simplex viruses, according to researchers at Johns Hopkins and Harvard universities and the National Institutes of Health.

12 Aug 2015

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet.

8 Jun 2015

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.

4 Jun 2015